Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)

Evaluation of the reasons for discontinuation of therapy with Janus kinase inhibitors (JAKi) may provide a clue to their more effective use.Objective : to analyze the survival of tofacitinib (TOFA) therapy and the reasons for its discontinuation in rheumatoid arthritis (RA) in real clinical practice...

Full description

Bibliographic Details
Main Authors:	G. I. Gridneva, E. S. Aronova, B. S. Belov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2022-12-01
Series:	Современная ревматология
Subjects:	tofacitinib therapy survival retention on therapy rheumatoid arthritis reasons for discontinuation of therapy
Online Access:	https://mrj.ima-press.net/mrj/article/view/1369

Similar Items

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
by: Naoki Iwamoto, et al.
Published: (2021-07-01)

Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
by: Yi Lu, et al.
Published: (2023-05-01)

Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
by: Marino Paroli, et al.
Published: (2023-08-01)

Efficacy of tofacitinib on rheumatoid arthritis: A retrospective single-center cohort study
by: Yuhui Qi, et al.
Published: (2023-09-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis
by: Dorottya Kacsándi, et al.
Published: (2023-10-01)

Seronegative cutaneous rheumatoid nodules with positive response to tofacitinib
by: Matthew Helm, MD, et al.
Published: (2024-08-01)

Reactivation of latent tuberculosis infection following initiation of tofacitinib therapy for rheumatoid arthritis: A case report
by: Nishant Johri, et al.
Published: (2023-12-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
by: Paola Di Benedetto, et al.
Published: (2021-08-01)

The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study
by: Claudia Di Muzio, et al.
Published: (2024-01-01)

Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis
by: Monika Czókolyová, et al.
Published: (2022-10-01)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
by: Jing-Wen Chen, et al.
Published: (2022-12-01)

Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population
by: Santos-Moreno P, et al.
Published: (2022-07-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach
by: Boglárka Soós, et al.
Published: (2022-11-01)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
by: Zhan-Guo Li, et al.
Published: (2018-01-01)

Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6
by: Piero Ruscitti, et al.
Published: (2022-05-01)

Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
by: M. Tasso, et al.
Published: (2022-12-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-07-01)

Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup—A Multicenter Study
by: Marta Priora, et al.
Published: (2024-12-01)

Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis – why cardiovascular risk factors do not equate to overt risk
by: Anna Felis-Giemza, et al.
Published: (2024-01-01)

Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
by: Boyce EG, et al.
Published: (2016-01-01)

Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
by: M. Vomero, et al.
Published: (2022-03-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

An effective strategy with tofacitinib for the management of focal myositis with rheumatoid arthritis: a case report
by: Jing Pan, et al.
Published: (2024-12-01)

Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports
by: Tetsuo Kobayashi, et al.
Published: (2019-04-01)

Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study
by: Giuseppe Germanò, et al.
Published: (2022-09-01)

Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
by: Ian F. J. Pirker, et al.
Published: (2018-11-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
by: Gustavo Citera, et al.
Published: (2023-11-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
by: A. E. Karateev, et al.
Published: (2021-09-01)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
by: Jürgen Wollenhaupt, et al.
Published: (2019-04-01)

Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
by: Seong-Kyu Kim, et al.
Published: (2023-04-01)

Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review
by: Matic Mihevc, et al.
Published: (2021-04-01)